Question 1

What are the documented side effects of C-peptide?

Accepted Answer

For C-peptide given as a therapy, the published summaries behind this page do not list any. That is an absence in the reporting, which is not the same as a record of no harm. What they do describe are intended effects, and a 2017 review says findings from multiple studies now suggest that C-peptide may beneficially affect the disturbed metabolic and pathophysiological pathways leading to the development of diabetic nephropathy. Pathophysiological means the processes that go wrong in a disease, and diabetic nephropathy is kidney damage from diabetes. The human part of that evidence is short, since the review places it in short-term studies of patients with type 1 diabetes. A short study built to look for a kidney change is not built to find an uncommon side effect, and a review summary of it would not be the place such an effect was reported. Read the silence as a gap in what was looked for, not as reassurance.

Question 2

Is C-peptide safe to take?

Accepted Answer

Nobody can answer that from these sources, and the reason is structural rather than alarming. Every person described as receiving C-peptide had type 1 diabetes, received it briefly, and was studied for a kidney, nerve or blood-cell marker. The one direct caution concerns the body's own level, where a 2023 review says it is complex how C-peptide is related to diabetic complications. The same review adds that both deficiencies and overproduction can lead to complications, but their mechanisms of action may be different, so more is not simply better. It goes on to say that the complex pattern of the relationship between C-peptide and diabetic chronic complications has not yet been fully understood. That is the honest position. A peptide that is linked with harm at both ends of its range, studied for days rather than years, has a safety question that is open rather than answered either way.

Question 3

What side effects turned up in the immune therapy trials that tracked C-peptide?

Accepted Answer

Much of what a search for C-peptide side effects returns comes from trials that measured C-peptide while giving something else. In the 2013 teplizumab trial in 52 people with new type 1 diabetes, the most common adverse events were rash, transient upper respiratory infections, headache, and nausea. In a 2021 trial of an anti-interleukin-21 antibody with liraglutide in 308 adults, changes in immune cell subsets across groups were transient and mild. A 2026 real-world report on low-dose antithymocyte globulin in type 1 diabetes, a therapy that thins out certain immune cells, recorded no unexpected side effects. Each of these is a harm profile for an immune therapy, measured in people whose immune system was attacking their pancreas. C-peptide was the scoreboard in those trials and not the player, and none of their side effects can be read as an effect of C-peptide.

Question 4

What harms were reported in the cell transplant trials?

Accepted Answer

The cell therapy trials carry the heaviest harms in this literature, and again they belong to the transplant and the medicines given with it. In the 2025 zimislecel trial of 14 people with type 1 diabetes, two deaths occurred, one from a fungal infection of the brain lining called cryptococcal meningitis, and one from the worsening of dementia the person already had. A 2021 study of lab-grown cells placed under the skin of 15 patients reported no teratoma formation or severe graft-related adverse events, a teratoma being a lump of the wrong kinds of tissue. In a 2025 case report of gene-edited donor cells given with no drugs to hold back the immune system, four adverse events occurred, and none of them were serious or linked to the study drug. These are small, early studies, with follow-up of about a year or less. Neither the deaths nor the clean reports tell us anything about C-peptide, which in each case was only the test showing the new cells were at work.

Question 5

Can a C-peptide reading reveal harm from another medicine?

Accepted Answer

Yes, and this is the most useful safety role C-peptide has. A falling reading can be the first hard sign that a medicine has hurt the body's own insulin supply. A 2017 Danish case report on a cancer medicine called ipilimumab warned that diabetes is a rare and serious side effect of it, and that doctors should be aware of this because of how fast it comes on. A 2007 study set out to look for harm from ciclosporin, a transplant medicine, on how much insulin people made, and two of its eleven patients were withdrawn due to side effects and poor compliance. A 2022 crossover trial in 12 patients found that one heart medicine raised glucagon, the hormone that pushes blood sugar up, which may explain why their blood sugar handling got worse. In each case C-peptide was part of the proof of harm, and it was not the cause of it.

Question 6

Is a low reading linked with worse outcomes?

Accepted Answer

In one large group without diabetes, it was. That is an association in a registry, which is weaker than a trial, and it is a finding about the body's own output rather than about anything given. A 2017 registry study followed 1171 patients with ischemic stroke and no history of diabetes, estimating insulin-making function from fasting C-peptide. Those in the lowest quarter of that measure had a higher risk of stroke recurrence, with an adjusted hazard ratio of 3.57, compared with the highest quarter. The authors concluded that β-cell dysfunction was associated with an increased risk of 12-month poor prognosis in nondiabetic patients with ischemic stroke. A hazard ratio of 3.57 means a risk about three and a half times higher over the follow-up. It does not mean low C-peptide caused the second stroke, and it does not mean raising the reading would prevent one.

Question 7

What does C-peptide interact with?

Accepted Answer

In cells, with insulin's own signalling. In people, the interaction has not been tested as a safety question in any of the research behind this page. A 2004 review reports that, lacking a purified receptor, its authors still demonstrate C-peptide effects on distinct elements of the insulin signal transduction pathways, the chain of messages a cell passes on after insulin arrives. That matters for blood sugar in principle, since anything touching the insulin pathway could change how a cell handles glucose, but no human study among these sources measures it. Genes also shape the response, and a second 2004 review reports a gene variant associated with lower enzyme activity in patients with C-peptide deficiency either with type 1 or type 2 diabetes, but not in normal individuals. So the same level of C-peptide may not mean the same thing in two people with different versions of one gene. A result in cells describes a mechanism, and it does not tell anyone what an infusion would do to their blood sugar.

Question 8

Is C-peptide hard on the kidneys or liver?

Accepted Answer

The kidney evidence points toward protection rather than harm, and the liver barely handles C-peptide at all. The 1982 review in Diabetes Care says the liver takes up only a minimal fraction, and C-peptide is supposed to be mainly removed by the kidney. On kidney outcomes, a 2017 review reports that cohort studies of diabetic patients with combined islet and kidney transplants suggest that maintained C-peptide secretion is protective of renal graft function, renal graft meaning the transplanted kidney. Cohort studies follow groups without assigning anyone to anything, so they show an association and not a cause. Being cleared by an organ is also not the same as burdening it. What is missing is the ordinary safety check. None of the studies among the research behind this page reports a kidney or liver function panel in people given C-peptide, so the protective signal and the absence of a harm signal are both short-term and thin.

Question 9

Who was left out of the studies?

Accepted Answer

For the replacement studies, the summaries behind this page do not say. For the trials that tracked C-peptide, the entry rules are written down, and they mark the edges of what those results cover. The 2021 anti-interleukin-21 trial took adults aged 18-45 years with recently diagnosed type 1 diabetes and residual β-cell function, and excluded anyone with severe diabetic ketoacidosis within 2 weeks or with active or latent chronic infections. The 1990 nicotinamide trial enrolled only children and adolescents aged 6 to 18, all within six weeks of diagnosis. The large 2026 GRADE analysis took people aged 30 and over with type 2 diabetes and an HbA1c of 6.8%-8.5%. Older adults with long-standing type 1 diabetes and people with chronic infections sit outside the trials described above. A result from inside those limits does not carry to someone outside them.

Question 10

How long does the human safety record run?

Accepted Answer

For C-peptide given as therapy, short-term is the only length these summaries record. The trials that tracked the reading ran longer, and the longest follow-up comes from islet transplants. The 2013 teplizumab trial measured its main result 2 years after disease onset. The 2021 anti-interleukin-21 trial added an off-treatment observation period of 26 weeks after its 54 weeks of dosing. Islet transplant work reaches furthest, and a 2015 review describes a considerable decline in the initial insulin independence rates at eight years following the transplantation, alongside permanent C-peptide secretion. The newest cell therapies are much shorter, with the gene-edited case report describing its patient at 12 weeks after transplantation. Eight years of islet data describe transplanted cells, not C-peptide given by drip. The infusion record stays measured in days or weeks.

Question 11

Is C-peptide FDA approved, and what does that cover?

Accepted Answer

None of the research behind this page describes C-peptide approved as a medicine, by the FDA or by any other regulator. What has a regulatory life is the reading. A 2025 trial of an automated insulin pump sorted adults with insulin-treated type 2 diabetes into high C-peptide (n = 195) and low C-peptide (n = 59) groups based on criteria set by the Centers for Medicare & Medicaid Services. That is an insurance rule built on a laboratory figure, and it shows where C-peptide sits in regulation: as a measurement that decides eligibility, and not as something dispensed. A 2021 editorial also records that C-peptide fragments are given in immunotherapy of type 1 diabetes, which is a separate research use with its own record. Anything sold as C-peptide outside that research has no label, and no approval described in these sources reaches it.

Question 12

Why is the harm record for C-peptide this thin?

Accepted Answer

Because the therapy idea stalled before it produced the long trials that generate harm data. A 2023 review describes the arc in one line: replacement showed beneficial effects on diabetic complications in animal models when C-peptide is deficient, before the clinical trials disappointed. A 2021 editorial adds that the concept of C-peptide as a hormone is presently not supported, which removes much of the reason to keep giving it. Large, long safety records are built when something is heading for approval and wide use. C-peptide as a therapy never reached that stage in these sources, so its harm record is thin for the same reason its benefit record is thin. The measured effects that did turn up, on kidneys, nerves and red blood cells, are set out by outcome on the C-peptide benefits page, and the amounts and settings behind them are covered at the C-peptide dosage page.

C-peptide side effects and safety data